SCIO Scios Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
SCIO Scios Inc.

An SI Board Since October 1996

Posts	SubjectMarks	Bans	Symbol
1477	17	0	SCIO

Emcee: Rick Strange	Type: Unmoderated

Introduction Market Data Compact

Scios & Wyeth-Ayerst have announced an agreement to develop FIBLAST for neurological and cardiovascular disorders.

Wyeth-Ayerst, the pharmaceutical division of American Home Products, will make a $12million upfront payment in cash and will also pay Scios up to $32million in milestone payments upon achievement of all key development events. In addition, Wyeth-Ayerst will provide a $12million line of credit that Scios may draw upon from time to time to fund expansion of its manufacturing facilities for FIBLAST.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1477	Scios deal expands J&J's biotech presence By Paul Jacobs Mercury Ne	sim1	-	2/11/2003
1476	unless you sell naked puts strike 45 :-) cheers Stefaan	dalroi	-	2/10/2003
1475	Actually the stock is trading at a pretty skimpy discount from the $45 deal pric	Biomaven	-	2/10/2003
1474	From Reuters - <i>J&J said the deal is expected to close in the secon	tom pope	-	2/10/2003
1473	Well the shorts had fired one last unavailing desperate shot in the WSJ ahead of	Biomaven	-	2/10/2003
1472	Peter, in the current market environment, probably so. The fact that no other b	quidditch	-	2/10/2003
1471	Well so much for any hopes of a bidding war: <i> J&J to buy Scios	Biomaven	-	2/10/2003
1470	Aus, Making IV nitro the comparator in the natrecor trial was the FDA's sug	Biomaven	-	2/9/2003
1469	Sun Feb 9 05:53:10 2003 Arthritis Treatment in Transition By Ransdell Pierso	John McCarthy	-	2/9/2003
1468	I will continue to believe, until proven opposite, that 496 is not right molecul	Miljenko Zuanic	-	2/8/2003
1467	Dobar dan Miljenko. When you say <i>I will continue to believe, until	Casaubon	-	2/8/2003
1466	BUY SCLN...... never touted a stock so blatently in my life....but look at the c	Skywatcher	-	2/7/2003
1465	Congratulation to all who were long SCIO. Honestly, lately I was lining more t	Miljenko Zuanic	-	2/7/2003
1464	Peter, no, I mean that the marketing has been fierce... ...not that you overexa	Ausdauer	-	2/7/2003
1463	Here's a description of the BI compound: <i>p38 kinase inhibitors Pet	Biomaven	-	2/7/2003
1462	Suddenly the street discovers the potential of a P38 inhibitor: <i>Scios,	Biomaven	-	2/7/2003
1461	<<So it's not a breakthrough drug, but it doesn't have to be given	rkrw	-	2/7/2003
1460	By the way, here's a recent publication of the earlier results showing poten	Biomaven	-	2/7/2003
1459	Aus, <i> benefits have been greatly overexagerated</i> Certainly n	Biomaven	-	2/7/2003
1458	Peter, At some point in the future there will be outpatient Natrecor, implanted	Ausdauer	-	2/7/2003
1457	The bulk of what JNJ is paying for is Natrecor. If all they wanted was the P38 p	Biomaven	-	2/7/2003
1456	Maven, I suspect JNJ is interested in the arthritis drug. Increasing Natrecor s	Ausdauer	-	2/7/2003
1455	Here's their release: <i>Scios Comments on Discussions Regarding Pote	Biomaven	-	2/7/2003
1454	Peter, My thanks to you for opening my eyes to this one. It was your postings	JFitnich	-	2/7/2003
1453	This is one of my biggest positions, so I suppose I should be happy. But I'l	Biomaven	-	2/7/2003

Go to reply# or date (mm/dd/yy):